Sensorium Therapeutics to Present Phase 1a Data for SNTX-2643 at Psych Congress 2026

Early Clinical Data to Highlight Safety, Pharmacokinetics and Target Engagement in Anxiety Program

Sensorium Therapeutics, a clinical-stage biotechnology company focused on psychiatric and neurological disorders, announced that it will present Phase 1a clinical data for SNTX-2643 at Psych Congress 2026.

The conference will take place from September 15 to 19, 2026, in New Orleans, Louisiana.

SNTX-2643 is Sensorium's lead investigational therapy and is being developed for anxiety disorders, including social anxiety disorder and generalized anxiety disorder.

The upcoming presentation will provide early clinical information from the company's ongoing Phase 1a study in healthy adults. Researchers are evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profile of the therapy.

Phase 1a Study Is Evaluating SNTX-2643 in Healthy Adults

The Phase 1a study was designed to understand how SNTX-2643 behaves in the body and how it affects the central nervous system.

The study is randomized, double-blind and placebo-controlled, with an open-label food-effect cohort.

Participants receive a single dose of SNTX-2643 as part of the study's different evaluation groups.

Safety is the primary endpoint. Researchers are also measuring plasma pharmacokinetics and exploring pharmacodynamic activity and target engagement.

The study includes several different cohorts to provide a broader picture of the drug candidate.

Study Includes Dose Escalation and Target Engagement Testing

One part of the study involves single-ascending doses.

In simple terms, researchers give different groups of participants increasing doses of SNTX-2643. This helps them understand how the treatment is tolerated at different dose levels.

Another part of the study focuses on target engagement.

This cohort uses quantitative electroencephalography, or qEEG, to look at changes in brain activity following administration of SNTX-2643.

The researchers are using resting-state measurements, event-related potentials and an anxiety-inducing stimulus to examine whether the treatment produces measurable activity in the central nervous system.

Anxiety-Inducing Video Paradigm Will Be Used

The target engagement cohort includes an aversive video paradigm designed to produce an anxiety response in participants.

Researchers will then evaluate CNS pharmacodynamic activity following a single dose of SNTX-2643.

This approach is intended to provide information about whether the drug is affecting biological processes related to anxiety.

The results may also help researchers understand how the treatment interacts with its intended target before the program moves into larger patient studies.

Food-Effect Cohort Will Examine Drug Absorption

The Phase 1a study also includes a food-effect cohort.

This part of the study is designed to determine whether eating affects the rate or extent of SNTX-2643 absorption.

Understanding the effect of food can be important when designing how a medicine should be taken in later clinical studies and, eventually, in routine use if it is approved.

SNTX-2643 Is Being Developed as a New Approach to Anxiety Treatment

SNTX-2643 is the lead program from Sensorium's SENS-01 program.

The company is developing it for social anxiety disorder and generalized anxiety disorder, with the potential to evaluate the therapy in other central nervous system disorders.

Sensorium describes SNTX-2643 as a first-in-class state-selective serotonin modulator.

The drug is designed to work differently from commonly used anxiety medicines.

The company is developing SNTX-2643 with the goal of achieving a rapid onset of action while reducing unwanted effects outside its intended target.

Sensorium also believes the approach could potentially avoid some of the problems associated with existing treatments, including sedation and other adverse effects that can occur with benzodiazepines and selective serotonin reuptake inhibitors.

Why New Anxiety Treatments Are Still Needed

Anxiety disorders affect large numbers of people and can have a major impact on daily life.

Current treatments can work well for some patients, but they do not work equally well for everyone.

Some medicines can also take time to produce their full effects or cause side effects that make long-term treatment difficult.

This is one reason companies continue to look for therapies that can provide faster and more targeted effects.

Sensorium is attempting to address this need through a different approach to serotonin modulation.

The Phase 1a study is an early step, so the clinical data will be important for understanding whether the potential seen in preclinical research translates into humans.

Sensorium Will Present the Data at Psych Congress 2026

The Phase 1a results will be presented in a poster session at Psych Congress 2026.

The presentation is titled:

"The Novel Serotonin Transporter Modulator SNTX-2643: Results from a Pharmacokinetic and Target Engagement Evaluation in Healthy Adults."

The poster is listed as Poster Number 199.

The presentation will be given by Colville Brown, M.D., with Andrew J. Cutler, M.D., Colville Brown, M.D., Jacob Hooker, Ph.D., and Jerry Rosenbaum, M.D., listed as authors.

The poster presentation is scheduled for September 17 and September 18 at the New Orleans Ernest N. Morial Convention Center.

Sensorium plans to make the poster available on its website after the presentation.

What the Phase 1a Results Could Show

The upcoming data are expected to provide a better understanding of the safety and tolerability of SNTX-2643.

The pharmacokinetic results should also show how the drug is absorbed and behaves in the body following administration.

The exploratory pharmacodynamic data could provide additional information about whether SNTX-2643 is engaging its intended biological pathway.

The qEEG findings may be particularly useful because they could help show whether the treatment produces measurable changes in brain activity linked to its proposed mechanism.

These results will help guide the design of future clinical trials.

Next Steps for the SENS-01 Program

Sensorium is developing SNTX-2643 as the lead program in its broader SENS-01 development strategy.

The company expects the early clinical findings to help determine how the program moves into subsequent studies in people with anxiety disorders.

Future trials will need to evaluate the treatment in patients rather than healthy volunteers and determine whether the biological effects seen in Phase 1 translate into improvements in anxiety symptoms.

Additional clinical development will also be needed to establish the appropriate dose, safety profile and potential effectiveness of the therapy.

Sensorium's Broader CNS Pipeline

Sensorium Therapeutics is focused on developing small-molecule medicines for psychiatric and neurological disorders.

The company uses its proprietary SensAI discovery platform to identify drug candidates with differentiated mechanisms of action.

The platform combines chemistry, pharmacology, behavioral science and neuroscience to support drug discovery.

Sensorium's pipeline includes SNTX-2643, which is currently in Phase 1 development for anxiety disorders.

The company is also developing SENS-03, a preclinical program focused on treatment-resistant epilepsy.

Another program, SENS-08, is a National Institutes of Health-supported preclinical program targeting cognitive enhancement.

Sensorium was founded by researchers from Harvard University and Massachusetts General Hospital and is building its pipeline around the relationship between brain biology, disease mechanisms and drug response.

Psych Congress Presentation Details

The SNTX-2643 presentation will take place at Psych Congress 2026 in New Orleans, Louisiana.

The presentation details are:

Title: The Novel Serotonin Transporter Modulator SNTX-2643: Results from a Pharmacokinetic and Target Engagement Evaluation in Healthy Adults

Poster Number: 199

Presenting Author: Colville Brown, M.D.

Dates: September 17 and September 18, 2026

Location: New Orleans Ernest N. Morial Convention Center

The presentation will give researchers and healthcare professionals an early look at the clinical development of SNTX-2643 and the data generated from its Phase 1a program.